LDLR and neoplasm: Recently, in vitro and in vivo studies of EGFRvIII-expressing GBM models revealed a non-oncogene addiction to lipoproteins, due to the activation of the PI3K/AKT–SREBP–LDLR signalling axis, highlighting a metabolic ‘Achilles heel’ of tumour specificity related to the homeostatic control of intracellular cholesterol levels [7,8,9].